Shots:

• The P-III (KEYNOTE-B21) study assesses Keytruda + CT with/without radiotherapy vs PBO to treat newly-diagnosed patients (n=1,095) with high-risk endometrial cancer post-surgery with curative intent
• The study did not meet the 1EP of DFS while OS was not tested due to non-attainment of DFS; safety profile was favorable without any new signals. Full assessment continues with results anticipated at a scientific community
• Merck’s endometrial carcinoma trials include NRG-GY018 study of Keytruda + SoC CT followed by Keytruda alone, with the US FDA’s priority review (PDUFA date: Jun 21, 2024); KEYNOTE-C93 study of Keytruda vs CT & MK-2870-005 study of sacituzumab tirumotecan vs physicians' choice treatment in patients previously treated with Pt-based CT & immunotx.

Ref: Merck | Image: Merck

Related News:- Merck Reports the P-III (KEYNOTE-811) Study Data of Keytruda Plus Trastuzumab and Chemotherapy for G/GEJ Adenocarcinoma

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com